These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20406855)

  • 21. Lubiprostone: a novel treatment for chronic constipation.
    Lacy BE; Levy LC
    Clin Interv Aging; 2008; 3(2):357-64. PubMed ID: 18686757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
    Chamberlain SM; Rao SS
    Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders.
    Ginzburg R; Ambizas EM
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1091-7. PubMed ID: 18680443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series.
    O'Brien CE; Anderson PJ; Stowe CD
    Ann Pharmacother; 2010 Mar; 44(3):577-81. PubMed ID: 20179256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study.
    Fukudo S; Hongo M; Kaneko H; Ueno R
    Neurogastroenterol Motil; 2011 Jun; 23(6):544-e205. PubMed ID: 21303430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lubiprostone for constipation and irritable bowel syndrome with constipation.
    Tuteja AK; Rao SS
    Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):727-33. PubMed ID: 19090733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly.
    Gras-Miralles B; Cremonini F
    Clin Interv Aging; 2013; 8():191-200. PubMed ID: 23439964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
    Johanson JF; Ueno R
    Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neural influences on human intestinal epithelium in vitro.
    Krueger D; Michel K; Zeller F; Demir IE; Ceyhan GO; Slotta-Huspenina J; Schemann M
    J Physiol; 2016 Jan; 594(2):357-72. PubMed ID: 26527433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lubiprostone for the treatment of opioid-induced bowel dysfunction.
    Wong BS; Camilleri M
    Expert Opin Pharmacother; 2011 Apr; 12(6):983-90. PubMed ID: 21385112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia.
    Schiffhauer ES; Vij N; Kovbasnjuk O; Kang PW; Walker D; Lee S; Zeitlin PL
    Am J Physiol Lung Cell Mol Physiol; 2013 Mar; 304(5):L324-31. PubMed ID: 23316067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of noradrenaline and somatostatin on basal and stimulated mucosal ion transport in the guinea-pig small intestine.
    Keast JR; Furness JB; Costa M
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Aug; 333(4):393-9. PubMed ID: 2877401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lubiprostone: in constipation-predominant irritable bowel syndrome.
    Carter NJ; Scott LJ
    Drugs; 2009 Jun; 69(9):1229-37. PubMed ID: 19537839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
    Norimatsu Y; Moran AR; MacDonald KD
    Biochem Biophys Res Commun; 2012 Sep; 426(3):374-9. PubMed ID: 22960173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanical stimulation releases nucleotides that activate P2Y1 receptors to trigger neural reflex chloride secretion in guinea pig distal colon.
    Cooke HJ; Xue J; Yu JG; Wunderlich J; Wang YZ; Guzman J; Javed N; Christofi FL
    J Comp Neurol; 2004 Jan; 469(1):1-15. PubMed ID: 14689470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lubiprostone targets prostanoid EP₄ receptors in ovine airways.
    Cuthbert AW
    Br J Pharmacol; 2011 Jan; 162(2):508-20. PubMed ID: 20883477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lubiprostone: viewpoints.
    Schiller LR; Camilleri M
    Drugs; 2006; 66(6):880-1. PubMed ID: 16706563
    [No Abstract]   [Full Text] [Related]  

  • 38. Short Chain Fatty Acids Effect on Chloride Channel ClC-2 as a Possible Mechanism for Lubiprostone Intestinal Action.
    Catalán MA; Julio-Kalajzić F; Niemeyer MI; Cid LP; Sepúlveda FV
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lubiprostone for the treatment of functional constipation in children.
    Hyman PE; Di Lorenzo C; Prestridge LL; Youssef NN; Ueno R
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):283-91. PubMed ID: 24048162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.
    Lembo AJ; Johanson JF; Parkman HP; Rao SS; Miner PB; Ueno R
    Dig Dis Sci; 2011 Sep; 56(9):2639-45. PubMed ID: 21769655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.